Pregabalin + Lorazepam + Pregabalin + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Generalized Anxiety Disorder
Conditions
Generalized Anxiety Disorder
Trial Timeline
May 1, 2009 → Apr 1, 2012
NCT ID
NCT00624780About Pregabalin + Lorazepam + Pregabalin + Placebo
Pregabalin + Lorazepam + Pregabalin + Placebo is a approved stage product being developed by Pfizer for Generalized Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00624780. Target conditions include Generalized Anxiety Disorder.
What happened to similar drugs?
6 of 20 similar drugs in Generalized Anxiety Disorder were approved
Approved (6) Terminated (3) Active (12)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00624780 | Approved | Completed |
Competing Products
20 competing products in Generalized Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 38 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 47 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine + Placebo | Eli Lilly | Approved | 43 |
| Ixekizumab | Eli Lilly | Approved | 43 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 35 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 43 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 42 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 27 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 29 |
| Escitalopram | AbbVie | Approved | 43 |
| Adalimumab | AbbVie | Phase 3 | 40 |